Resource Summary Report

Generated by NIF on Jul 30, 2026

VVT1

RRID:Addgene_65779
Type: Plasmid

Proper Citation

RRID:Addgene_65779

Plasmid Information

URL: http://www.addgene.org/65779

Proper Citation: RRID:Addgene_65779

Insert Name: SaCas9 gRNA backbone, without spacer sequence

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: PMID:26098369

Vector Backbone Description: Backbone Marker:Joung lab (Addgene Plasmid # 43860); Vector Backbone:MLM3636; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

Comments: Use BsmBI sites to insert sgRNA spacer sequence into the vector. See the supplemental document "Joung Lab gRNA Cloning Protocol" for more details. UPDATE 5/31/2016: The Joung Lab recommends using BPK2660 (Addgene plasmid # 70709) instead of VVT1 as an SaCas9 guide RNA cloning vector, as guide RNAs cloned into BPK2660 are more effective than those cloned into VVT1. The difference in efficacy is due to VVT1 containing the full length guide RNA (predicted from the natural CRISPR sequence in S. aureus), whereas BPK2660 uses a truncated gRNA that is more effective. For the same oligo/spacer, the rate of mutagenesis is greater using BPK2660. See Kleinstiver et al., 2015 Nat Biotech for additional information on the truncated gRNA plasmid (https://www.ncbi.nlm.nih.gov/pubmed/26524662).

Plasmid Name: VVT1

Record Creation Time: 20220422T222414+0000

Record Last Update: 20260725T075012+0000

Ratings and Alerts

No rating or validation information has been found for VVT1.

No alerts have been found for VVT1.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Khosravi MA, et al. (2019) Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. European journal of pharmacology, 854, 398.